"HL-60人原髓細胞白血病細胞代次低|培養(yǎng)基|送STR圖譜

傳代比例：1:2-1:4(首次傳代建議1:2)

生長特性：懸浮生長

細胞系的應用：1)免疫組化研究2)RNA干擾研究3)藥物作用研究4)慢病毒轉染研究等其它應用。細胞系通常用于實驗研究，如增殖、遷移、侵襲等。細胞系在多個領域的研究中被廣泛應用，包括基礎醫(yī)學、臨床試驗、藥物篩選和分子生物學研究。這些研究不僅在中國，也在日本、美國和歐洲等多個國家和地區(qū)進行。

換液周期：每周2-3次

RT112 Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：RS4;11細胞、P 815細胞、HaCaT細胞

Granta519 Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：TE15細胞、Balb/c 3T3細胞、Ishikawa細胞

NCIH322 Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：SW-1116細胞、H-865細胞、Henrietta Lacks cells細胞

HL-60人原髓細胞白血病細胞代次低|培養(yǎng)基|送STR圖譜

背景信息：該細胞由CollinsSJ從一位患有急性早幼粒細胞性白血病的３６歲白人女性的外周血中分離建立；可自發(fā)分化，或在鹽、次黃嘌呤、佛波醇肉豆蔻(,TPA)、DMSO(１%to１.５%)、D和視黃的刺激下發(fā)生分化；刺激后可分泌TNF-α。該細胞具有吞噬活性和趨化反應，癌基因myc陽性，表達補體受體和FcR。

┈訂┈購(技術服務)┈熱┈線：1┈3┈6┈4┈1┈9┈3┈0┈7┈9┈1【微信同號】┈Q┈Q：3┈1┈8┈0┈8┈0┈7┈3┈2┈4；

DSMZ菌株保藏中心成立于1969年，是德國的國家菌種保藏中心。該中心一直致力于細菌、真菌、質(zhì)粒、抗菌素、人體和動物細胞、植物病毒等的分類、鑒定和保藏工作。DSMZ菌種保藏中心是歐洲規(guī)模最大的生物資源中心，保藏有動物細胞500多株。Riken BRC成立于1920年，是英國的國家菌種保藏中心。該中心一直致力于細菌、真菌、植物病毒等的分類、鑒定和保藏工作。日本Riken BRC(Riken生物資源保藏中心)是全球三大典型培養(yǎng)物收集中心之一。Riken保藏中心提供了很多細胞系。在世界范圍內(nèi)，這些細胞系，都在醫(yī)學、科學和獸醫(yī)中具有重要意義。Riken生物資源中心支持了各種學術、健康、食品和獸醫(yī)機構的研究工作，并在世界各地不同組織的微生物實驗室和研究機構中使用。

產(chǎn)品包裝：復蘇發(fā)貨：T25培養(yǎng)瓶(一瓶)或凍存發(fā)貨：1ml凍存管(兩支)

來源說明：細胞主要來源ATCC、ECACC、DSMZ、RIKEN等細胞庫

HL-60人原髓細胞白血病細胞代次低|培養(yǎng)基|送STR圖譜

物種來源：人源、鼠源等其它物種來源

C3H/10T1/2-clone8 Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：MSF細胞、SW-962細胞、NSC-34細胞

U-2932 Cells;背景說明：彌漫大B淋巴瘤；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：Hs 839.T細胞、P3HR1細胞、NRK52E細胞

C17 Cells;背景說明：神經(jīng)干細胞；C５７BL/６ x CD-１;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：MDA-453細胞、SK-MEL-31細胞、Tn5B1-4細胞

NCIH1688 Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：NCI-H23細胞、AGS細胞、786-0WT細胞

┈訂┈購(技術服務)┈熱┈線：1┈3┈6┈4┈1┈9┈3┈0┈7┈9┈1【微信同號】┈Q┈Q：3┈1┈8┈0┈8┈0┈7┈3┈2┈4；

形態(tài)特性：淋巴母細胞樣

細胞傳代培養(yǎng)實驗：體外培養(yǎng)的原代細胞或細胞株要在體外持續(xù)地培養(yǎng)就必須傳代，以便獲得穩(wěn)定的細胞株或得到大量的同種細胞，并維持細胞種的延續(xù)。培養(yǎng)的細胞形成單層匯合以后，由于密度過大生存空間不足而引起營養(yǎng)枯竭，將培養(yǎng)的細胞分散，從容器中取出，以１:２或１:３以上的比率轉移到另外的容器中進行培養(yǎng)，即為傳代培養(yǎng)；細胞“一代”指從細胞接種到分離再培養(yǎng)的一段期間，與細胞世代或倍增不同。在一代中，細胞培增３～６次。細胞傳代后，一般經(jīng)過三個階段：游離期、指數(shù)增生期和停止期。常用細胞分裂指數(shù)表示細胞增殖的旺盛程度，即細胞群的分裂相數(shù)/１００個細胞。一般細胞分裂指數(shù)介于０.２％～０.５％，腫瘤細胞可達３～５％；細胞接種２～３天分裂增殖旺盛，是活力ZuiHAO時期，稱指數(shù)增生期(對數(shù)生長期)，適宜進行各種試驗。實驗步驟：１.將長成的培養(yǎng)細胞從二氧化碳培養(yǎng)箱中取出，在超凈工作臺中倒掉瓶內(nèi)的培養(yǎng)，加入少許消化。(以面蓋住細胞為宜)，靜置５～１０分鐘。２.在倒置鏡下觀察被消化的細胞，如果細胞變圓，相互之間不再連接成片，這時應立即在超凈臺中將消化倒掉，加入３～５ml新鮮培養(yǎng)，吹打，制成細胞懸。３.將細胞懸吸出２ml左右，加到另一個培養(yǎng)瓶中并向每個瓶中分別加３ml左右培養(yǎng)，蓋HAO瓶塞，送回二氧化碳培養(yǎng)箱中，繼續(xù)進行培養(yǎng)。一般情況，傳代后的細胞在２小時左右就能附著在培養(yǎng)瓶壁上，２～４天就可在瓶內(nèi)形成單層，需要再次進行傳代。

MADB106 Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：JEG3細胞、SUM159PT細胞、Hs604T細胞

SU8686 Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２傳代；;生長特性：貼壁生長;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：BRL3A細胞、PANC-28細胞、LuCL4細胞

Wayne State University-Head and Neck 13 Cells;背景說明：舌鱗癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：NU-GC-4細胞、ND7/23細胞、H1792細胞

HO-8910 Cells;背景說明：HO-８９１０細胞株是１９９４年從一位５１歲的中國卵巢癌患者腹水中建立的。 轉移到裸鼠中形成的腫瘤集聚與患者原病灶處的形態(tài)一致。;傳代方法：消化３-５分鐘。１：２。３天內(nèi)可長滿。;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關產(chǎn)品有：H2081細胞、LA-795細胞、SUM159PT細胞

SNG-M Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：多邊形;相關產(chǎn)品有：SKMEL5細胞、OVCA432細胞、CCC-HIE-2細胞

P3/X63-Ag8 Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：MHCC 97細胞、MOVAS細胞、HCC-366細胞

H-1781 Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：RD-2細胞、CHG-5細胞、HSC4細胞

H1563 Cells;背景說明：詳見相關文獻介紹;傳代方法：１：３-１：４傳代；每周換液２次。;生長特性：貼壁生長;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：GM00346細胞、T98細胞、MT2細胞

HMEC1 Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮細胞樣;相關產(chǎn)品有：LTEP-sm 1細胞、PCI-4B細胞、MDA-MB-134 VI細胞

NCI-H508 Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：293-H細胞、NCI660細胞、JVM3細胞

Mc Ardle 7777 Cells;背景說明：肝癌；雌性；Buffalo;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：PLC-PRF-5細胞、MBMEC細胞、SUDHL-6細胞

SUM159PT Cells;背景說明：乳腺癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：DMS153細胞、KMH2細胞、BJA-B-1細胞

SLK Cells;背景說明：肉瘤;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：SUM-52-PE細胞、SK_N_BE2C細胞、CAMA細胞

Hep-G2 Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：Emory University-2細胞、FK81細胞、CCC-HSF-1細胞

KYSE-450 Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：MHHCALL2細胞、LA-N-1細胞、SW480細胞

BS-C-1 Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：U87-MG細胞、RCC-4細胞、H-1693細胞

SK-N-BE-2 Cells;背景說明：１９７２年１１月從一們多次化療及放療的擴散性神經(jīng)母細胞瘤患兒骨髓穿刺物中建立了SK-N-BE(２)神經(jīng)母細胞瘤細胞株。 該細胞顯示中等水平的多巴胺-β-羥基酶活性。 有報道稱SK-N-BE(２)細胞的飽和濃度超過１x１０６細胞/平方厘米。細胞形態(tài)多樣，有的有長突觸，有的呈上皮細胞樣。 細胞會聚集，形成團塊并浮起;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮細胞樣;相關產(chǎn)品有：ID8/MOSEC細胞、BpRc1細胞、SK-CO-1細胞

Ab90 Cells(提供STR鑒定圖譜)

Abcam Raji HSPA2 KO Cells(提供STR鑒定圖譜)

Ban Cells(提供STR鑒定圖譜)

BayGenomics ES cell line RRR573 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line YTA072 Cells(提供STR鑒定圖譜)

CHA-hES19 Cells(提供STR鑒定圖譜)

DA01689 Cells(提供STR鑒定圖譜)

DD1247 Cells(提供STR鑒定圖譜)

GM01882 Cells(提供STR鑒定圖譜)

RT-BM 1 Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：成神經(jīng)細胞;相關產(chǎn)品有：B95.8細胞、SK MEL-28細胞、CemT4細胞

HL-60人原髓細胞白血病細胞代次低|培養(yǎng)基|送STR圖譜

Karpas-422 Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：Colon 38細胞、T.T細胞、Caco-2/ATCC細胞

Hs839T Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２傳代，２-３天換液１次。;生長特性：貼壁生長;形態(tài)特性：成纖維細胞;相關產(chǎn)品有：U-87MG ATCC細胞、PANC0203細胞、SK-Hep1細胞

HANK1 Cells;背景說明：NK/T細胞淋巴瘤；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：MCA-38細胞、H-1781細胞、NCI-H322細胞

PLC/PRF/5 Cells;背景說明：該細胞系分泌乙肝病毒表面抗原（HBsAg）。 此細胞系原先被支原體污染，后用BM-cycline去除支原體;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關產(chǎn)品有：Ramos.G6.C10細胞、HEY A8細胞、OS-RC-2細胞

NIH:OVCAR-8 Cells;背景說明：卵巢癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：X63-Ag8.653細胞、QBI-HEK 293A細胞、IEC-6細胞

3H5 [Mouse hybridoma against HNK-1] Cells(提供STR鑒定圖譜)

NPC-TW01 Cells;背景說明：鼻咽癌;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：Pfeiffer細胞、H1770細胞、C57/B6-L細胞

C17.2 Cells;背景說明：神經(jīng)干細胞；C５７BL/６ x CD-１;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：U 138 MG細胞、Eca109細胞、U266S細胞

10RGB Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：OCM1A細胞、TKB-1細胞、CEM-T4細胞

L-1210 Cells;背景說明：該細胞源于用０.２%甲基膽蒽（溶解）涂抹雌性小鼠的皮膚誘發(fā)的腫瘤，鼠痘病毒陰性。;傳代方法：１：２傳代;生長特性：懸浮生長;形態(tài)特性：淋巴母細胞樣;相關產(chǎn)品有：Cattle chondrocytes細胞、3T3J2細胞、MJ細胞

J111 Cells;背景說明：單核細胞白血病;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：NCIH650細胞、Hs819T細胞、University of Michigan-Urothelial Carcinoma-14細胞

32D clone3 Cells;背景說明：骨髓淋巴瘤；C３H/HeJ;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：A9細胞、4T1-A細胞、PANC-02-03細胞

Homo sapiens No. 578, tumor cells Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：HS852.T細胞、NCI-H146細胞、Giant Cell Tumor細胞

AM-38 Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮細胞;相關產(chǎn)品有：NRK52E細胞、EBNA-293細胞、HN-6細胞

GM11876 Cells(提供STR鑒定圖譜)

HAP1 DHTKD1 (-) 3 Cells(提供STR鑒定圖譜)

IOSE-Mar Cells;背景說明：卵巢；上皮細胞；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：4T1-A細胞、GM02132細胞、SEG1細胞

LIXC-002 Cells;背景說明：詳見相關文獻介紹;傳代方法：１：３傳代,３-４天傳１次;生長特性：貼壁生長;形態(tài)特性：上皮細胞樣;相關產(chǎn)品有：B4G12細胞、MRC9細胞、M059J細胞

Colon 26 Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：Jiyoye (P-2003)細胞、Ramos細胞、MHCC97細胞

ARPE19 Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關產(chǎn)品有：Balb/3T3-4-Cl31細胞、U 937細胞、IM 9細胞

HCC1588 Cells;背景說明：肺鱗癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：H-211細胞、MDA-kb2細胞、H-3255細胞

EOC 20 Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：SK-N-BE(1)n細胞、HRMC細胞、CORL23細胞

HRA 19 Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：Rat Lung Epithelial-6-T-antigen Negative細胞、NCI-H2444細胞、L02細胞

ZYM-SVEC01 Cells;背景說明：靜脈血管內(nèi)皮 Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：EB-1細胞、HOS-143B細胞、KTCTL-140細胞

HHUi003-B Cells(提供STR鑒定圖譜)

IOSE-53 Cells(提供STR鑒定圖譜)

Ma-5 Cells(提供STR鑒定圖譜)

ND07920 Cells(提供STR鑒定圖譜)

PF8-2-112-1 Cells(提供STR鑒定圖譜)

UCSD025i-13-4 Cells(提供STR鑒定圖譜)

ZR-75-1 BCAR4 clone 2B Cells(提供STR鑒定圖譜)

HAP1 TET1 (-) TET2 (-) 1 Cells(提供STR鑒定圖譜)

HCC-44 Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：NU-GC-2細胞、BLO11細胞、TH1細胞

CHL1 Cells;背景說明：詳見相關文獻介紹;傳代方法：１：６—１：１０傳代;生長特性：貼壁生長;形態(tài)特性：上皮細胞;相關產(chǎn)品有：MBMEC細胞、NCI-H220細胞、MDA157細胞

RPMI1788 Cells;背景說明：B淋巴細胞；EBV轉化;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：NCI-H1436細胞、UM-UC14細胞、NCI-H1436細胞

PZ-HPV-7 Cells;背景說明：前列腺上皮細胞；HPV１８轉化；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：NCI-SNU-216細胞、174xCEM.T2細胞、HEK-293FT細胞

HOS/MNNG Cells;背景說明：骨肉瘤；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：H-2347細胞、Centre Antoine Lacassagne-51細胞、JROECL19細胞

HOS/MNNG Cells;背景說明：骨肉瘤；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：H-2347細胞、Centre Antoine Lacassagne-51細胞、JROECL19細胞

GM00215 Cells;背景說明：肺；自發(fā)永生；雄性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：OS-RC-2細胞、NCIH524細胞、OCI AML2細胞

KYSE-410 Cells;背景說明：食管鱗癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：TE1細胞、SKMEL-1細胞、BTT739細胞

GM16136 Cells;背景說明：肺；自發(fā)永生；雄性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：RGM1細胞、MUS-M1細胞、C3H10T1-2細胞

HCC95 Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：RN-c細胞、Neuro-2a細胞、SV-HUC細胞

HO-8910 PM Cells;背景說明：高轉移卵巢癌 Cells;傳代方法：消化３-５分鐘。１：２。３天內(nèi)可長滿。;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關產(chǎn)品有：CL-40細胞、H-2227細胞、NCI-H345細胞

Hos TE-85 Cells;背景說明：骨肉瘤；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：MS1細胞、H650細胞、ACC3細胞

H-2135 Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：ROS17/28細胞、SKRC20細胞、Epstein-Barr-1細胞

H69C Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２—１：４傳代，每周換液２次;生長特性：懸浮生長，聚團;形態(tài)特性：聚團懸浮;相關產(chǎn)品有：H522細胞、MEF (CF-1)細胞、Jurkat E6-1細胞

NCI-SNU-1040 Cells;背景說明：結腸癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：DHL-2細胞、NIE 115細胞、H-1417細胞

SES-MaBr-3 Cells(提供STR鑒定圖譜)

HL-60 Clone 15 Cells;背景說明：詳見相關文獻介紹;傳代方法：維持細胞濃度在１×１０５-１×１０６/ml,每２-３天換液１次。;生長特性：懸浮生長;形態(tài)特性：淋巴母細胞樣;相關產(chǎn)品有：HHUA細胞、Roswell Park Memorial Institute 7666細胞、TE-6細胞

SNUC2A Cells;背景說明：詳見相關文獻介紹;傳代方法：每周兩次換液;生長特性：松散附著、多單元的聚合;形態(tài)特性：上皮細胞樣;相關產(chǎn)品有：A 549細胞、Panc_02_03細胞、Michigan Cancer Foundation-12A細胞

COLO 824 Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：KY-270細胞、NP-69細胞、HEK293-EBNA細胞

SuperTube Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：H1930細胞、TGW-I-nu細胞、LM6細胞

MRC 5 Cells;背景說明：MRC-５細胞系來自１４周齡男性胎兒的正常肺組織，該細胞老化前能傳代４２~４６個倍增時間。;傳代方法：１：２-１：５傳代；每周１-２次。;生長特性：貼壁生長;形態(tài)特性：成纖維細胞樣;相關產(chǎn)品有：BE2-C細胞、PE CA PJ34細胞、RC-4B細胞

FOX-NY Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：A-875細胞、C8161細胞、MLO-Y4細胞

HL-60人原髓細胞白血病細胞代次低|培養(yǎng)基|送STR圖譜

Huh 7.5 Cells;背景說明：肝癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：MiaPaCa2細胞、Lewis Lung Cancer細胞、SUM 190細胞

SKRC-52 Cells;背景說明：腎癌；縱隔膜轉移;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：VA-ES-BJ細胞、Ly19細胞、Sci-1細胞

DoTc2 Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２—１：３傳代，每周換液２—３次;生長特性：貼壁生長　;形態(tài)特性：上皮樣;相關產(chǎn)品有：Hs 688(A).T細胞、FU-OV-1細胞、MV4:11細胞

HRA 19 Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：Rat Lung Epithelial-6-T-antigen Negative細胞、FC33細胞、SVG(P12)細胞

LN382 Cells;背景說明：膠質(zhì)瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：526mel細胞、NCI-H28細胞、LN-382細胞

L-363 Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關產(chǎn)品有：H2342細胞、TE-7細胞、DoTc2細胞

HEK293FT Cells;背景說明：該細胞穩(wěn)定表達SV４０大T抗原，并且促進最適病毒產(chǎn)物的產(chǎn)生。;傳代方法：１：２傳代;生長特性：懸浮生長;形態(tài)特性：圓形;相關產(chǎn)品有：Evsa T細胞、SUM-52PE細胞、Tokyo Medical and Dental university 8細胞

Malme-3 M Cells;背景說明：詳見相關文獻介紹;傳代方法：１：２-１：４傳代，２天換液１次。;生長特性：混合生長;形態(tài)特性：成纖維細胞;相關產(chǎn)品有：RIN-m5F細胞、MDA-MB-468細胞、SUM149PT細胞

BayGenomics ES cell line NPX025 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line XC366 Cells(提供STR鑒定圖譜)

CPTC-DDIT3-2 Cells(提供STR鑒定圖譜)

MAsg2 Cells(提供STR鑒定圖譜)

SC17.122 Cells(提供STR鑒定圖譜)

HPB/VP-16 Cells(提供STR鑒定圖譜)

" "PubMed=6255959; DOI=10.1016/0014-4827(81)90422-5

Olsson I., Olofsson T.

Induction of differentiation in a human promyelocytic leukemic cell line (HL-60). Production of granule proteins.

Exp. Cell Res. 131:225-230(1981)

PubMed=6945469; DOI=10.1016/0145-2126(81)90018-7

Major P.P., Griffin J.D., Minden M.D., Kufe D.W.

A blast subclone of the HL-60 human promyelocytic cell line.

Leuk. Res. 5:429-430(1981)

PubMed=6954533; DOI=10.1073/pnas.79.7.2194; PMCID=PMC346157

Westin E.H., Gallo R.C., Arya S.K., Eva A., Souza L.M., Baluda M.A., Aaronson S.A., Wong-Staal F.

Differential expression of the amv gene in human hematopoietic cells.

Proc. Natl. Acad. Sci. U.S.A. 79:2194-2198(1982)

PubMed=6091813; DOI=10.1182/blood.V64.5.1059.1059

Palumbo A., Minowada J., Erikson J., Croce C.M., Rovera G.

Lineage infidelity of a human myelogenous leukemia cell line.

Blood 64:1059-1063(1984)

PubMed=6582512; DOI=10.1073/pnas.81.2.568; PMCID=PMC344720

Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.

Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.

Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984)

PubMed=2858093; DOI=10.1073/pnas.82.3.790; PMCID=PMC397132

Wolf D., Rotter V.

Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells.

Proc. Natl. Acad. Sci. U.S.A. 82:790-794(1985)

PubMed=2985879; DOI=10.1016/0145-2126(85)90084-0

Drexler H.G., Gaedicke G., Minowada J.

Isoenzyme studies in human leukemia-lymphoma cell lines -- 1 carboxylic esterase.

Leuk. Res. 9:209-229(1985)

PubMed=3159941; DOI=10.1016/0145-2126(85)90134-1

Drexler H.G., Gaedicke G., Minowada J.

Isoenzyme studies in human leukemia-lymphoma cell lines -- III Beta-hexosaminidase (E.C. 3.2.1.30).

Leuk. Res. 9:549-559(1985)

PubMed=3860286

Bhalla K.N., Hindenburg A.A., Taub R.N., Grant S.

Isolation and characterization of an anthracycline-resistant human leukemic cell line.

Cancer Res. 45:3657-3662(1985)

PubMed=3874327; DOI=10.1016/0145-2126(85)90133-x

Drexler H.G., Gaedicke G., Minowada J.

Isoenzyme studies in human leukemia-lymphoma cells lines -- II. Acid phosphatase.

Leuk. Res. 9:537-548(1985)

PubMed=3311197; DOI=10.1182/blood.V70.5.1233.1233

Collins S.J.

The HL-60 promyelocytic leukemia cell line: proliferation, differentiation, and cellular oncogene expression.

Blood 70:1233-1244(1987)

DOI=10.1159/000415060

Morikawa S., Harada T., Katoh T.

Heterogeneity of cellular origins in human malignant lymphoma cell line derived from histo-monocytic lineage cells.

(In book chapter) Cellular, molecular, genetic approaches to immunodiagnosis and immunotherapy. 8th International conference on labeled antibodies, Tokyo, November 1985; Kano K., Mori S., Sugisaki T., Torisu M. (eds.); pp.373-380; Karger; Basel; Switzerland (1988)

PubMed=3335022

Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.

Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

Cancer Res. 48:589-601(1988)

PubMed=3422031; DOI=10.1182/blood.V71.1.242.242

Dalton W.T. Jr., Ahearn M.J., McCredie K.B., Freireich E.J., Stass S.A., Trujillo J.M.

HL-60 cell line was derived from a patient with FAB-M2 and not FAB-M3.

Blood 71:242-247(1988)

PubMed=2545346

Hindenburg A.A., Gervasoni J.E. Jr., Krishna S., Stewart V.J., Rosado M., Lutzky J., Bhalla K.N., Baker M.A., Taub R.N.

Intracellular distribution and pharmacokinetics of daunorubicin in anthracycline-sensitive and -resistant HL-60 cells.

Cancer Res. 49:4607-4614(1989)

PubMed=1970118; DOI=10.1128/mcb.10.5.2154-2163.1990; PMCID=PMC360563

Collins S.J., Robertson K.A., Mueller L.

Retinoic acid-induced granulocytic differentiation of HL-60 myeloid leukemia cells is mediated directly through the retinoic acid receptor (RAR-alpha).

Mol. Cell. Biol. 10:2154-2163(1990)

PubMed=2140233; DOI=10.1111/j.1440-1827.1990.tb01549.x

Nakano A., Harada T., Morikawa S., Kato Y.

Expression of leukocyte common antigen (CD45) on various human leukemia/lymphoma cell lines.

Acta Pathol. Jpn. 40:107-115(1990)

PubMed=1368402; DOI=10.1007/BF02540028

Schumpp-Vonach B., Schlaeger E.-J.

Growth study of lactate and ammonia double-resistant clones of HL-60 cells.

Cytotechnology 8:39-44(1992)

PubMed=1574572; DOI=10.2307/3578273

Dunphy E.J., Beckett M.A., Thompson L.H., Weichselbaum R.R.

Expression of the polymorphic human DNA repair gene XRCC1 does not correlate with radiosensitivity in the cells of human head and neck tumor cell lines.

Radiat. Res. 130:166-170(1992)

PubMed=8316623; DOI=10.2307/3578190

Evans H.H., Ricanati M., Horng M.-F., Jiang Q.-Y., Mencl J., Olive P.L.

DNA double-strand break rejoining deficiency in TK6 and other human B-lymphoblast cell lines.

Radiat. Res. 134:307-315(1993)

PubMed=8343448

Kajigaya Y., Sasaki H., Ikuta K., Matsuyama S., Hirabayashi Y., Inoue T.

Serum-free culture for leukemia cells.

Hum. Cell 6:49-56(1993)

PubMed=7630190

Zhou M.-X., Gu L.-B., James C.D., He J., Yeager A.M., Smith S.D., Findley H.W. Jr.

Homozygous deletions of the CDKN2 (MTS1/p16ink4) gene in cell lines established from children with acute lymphoblastic leukemia.

Leukemia 9:1159-1161(1995)

PubMed=8562479

Banerjee D., Lenz H.-J., Schnieders B., Manno D.J., Ju J.-F., Spears C.P., Hochhauser D., Danenberg K.D., Danenberg P.V., Bertino J.R.

Transfection of wild-type but not mutant p53 induces early monocytic differentiation in HL60 cells and increases their sensitivity to stress.

Cell Growth Differ. 6:1405-1413(1995)

PubMed=8558913

Morita S., Tsuchiya S., Fujie H., Itano M., Ohashi Y., Minegishi M., Imaizumi M., Endo M., Takano N., Konno T.

Cell surface c-kit receptors in human leukemia cell lines and pediatric leukemia: selective preservation of c-kit expression on megakaryoblastic cell lines during adaptation to in vitro culture.

Leukemia 10:102-105(1996)

PubMed=9434637; DOI=10.1006/excr.1997.3813

Piepmeier E.H., Kalns J.E., McIntyre K.M., Lewis M.L.

Prolonged weightlessness affects promyelocytic multidrug resistance.

Exp. Cell Res. 237:410-418(1997)

PubMed=9510473; DOI=10.1111/j.1349-7006.1998.tb00476.x; PMCID=PMC5921588

Hosoya N., Hangaishi A., Ogawa S., Miyagawa K., Mitani K., Yazaki Y., Hirai H.

Frameshift mutations of the hMSH6 gene in human leukemia cell lines.

Jpn. J. Cancer Res. 89:33-39(1998)

PubMed=9557624; DOI=10.1038/sj.leu.2400976

Mattii L., Barale R., Petrini M.

Use of the comet test in the evaluation of multidrug resistance of human cell lines.

Leukemia 12:627-632(1998)

PubMed=9607592

Ju J.-F., Banerjee D., Lenz H.-J., Danenberg K.D., Schmittgen T.D., Spears C.P., Schonthal A.H., Manno D.J., Hochhauser D., Bertino J.R., Danenberg P.V.

Restoration of wild-type p53 activity in p53-null HL-60 cells confers multidrug sensitivity.

Clin. Cancer Res. 4:1315-1322(1998)

PubMed=9737686; DOI=10.1038/sj.leu.2401112

Zhang W.-J., Ohnishi K., Shigeno K., Fujisawa S., Naito K., Nakamura S., Takeshita K., Takeshita A., Ohno R.

The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms.

Leukemia 12:1383-1391(1998)

PubMed=9738977; DOI=10.1111/j.1349-7006.1998.tb03275.x; PMCID=PMC5921886

Takizawa J., Suzuki R., Kuroda H., Utsunomiya A., Kagami Y., Joh T., Aizawa Y., Ueda R., Seto M.

Expression of the TCL1 gene at 14q32 in B-cell malignancies but not in adult T-cell leukemia.

Jpn. J. Cancer Res. 89:712-718(1998)

PubMed=10739008; DOI=10.1016/S0145-2126(99)00182-4

Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.

Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines.

Leuk. Res. 24:255-262(2000)

DOI=10.1016/B978-0-12-221970-2.50457-5

Drexler H.G.

The leukemia-lymphoma cell line factsbook.

(In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001)

PubMed=11226526; DOI=10.1016/S0145-2126(00)00121-1

Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.

Corrigendum to: Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines Leukemia Research 24 (2000), 255-262.

Leuk. Res. 25:275-278(2001)

PubMed=11416159; DOI=10.1073/pnas.121616198; PMCID=PMC35459

Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G., Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R., Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.

Short tandem repeat profiling provides an international reference standard for human cell lines.

Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001)

PubMed=12068308; DOI=10.1038/nature00766

Davies H.R., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.

Mutations of the BRAF gene in human cancer.

Nature 417:949-954(2002)

PubMed=12661003; DOI=10.1002/gcc.10196

Seitz S., Wassmuth P., Plaschke J., Schackert H.K., Karsten U., Santibanez-Koref M.F., Schlag P.M., Scherneck S.

Identification of microsatellite instability and mismatch repair gene mutations in breast cancer cell lines.

Genes Chromosomes Cancer 37:29-35(2003)

PubMed=16120335; DOI=10.1016/S1567-7249(03)00010-2

Levin B.C., Holland K.A., Hancock D.K., Coble M., Parsons T.J., Kienker L.J., Williams D.W., Jones M., Richie K.L.

Comparison of the complete mtDNA genome sequences of human cell lines -- HL-60 and GM10742A -- from individuals with pro-myelocytic leukemia and Leber hereditary optic neuropathy, respectively, and the inclusion of HL-60 in the NIST human mitochondrial DNA standard reference material -- SRM 2392-I.

Mitochondrion 2:387-400(2003)

PubMed=15843827; DOI=10.1038/sj.leu.2403749

Andersson A., Eden P., Lindgren D., Nilsson J., Lassen C., Heldrup J., Fontes M., Borg A., Mitelman F., Johansson B., Hoglund M., Fioretos T.

Gene expression profiling of leukemic cell lines reveals conserved molecular signatures among subtypes with specific genetic aberrations.

Leukemia 19:1042-1050(2005)

PubMed=16408098; DOI=10.1038/sj.leu.2404081

Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.

JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders.

Leukemia 20:471-476(2006)

PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433; PMCID=PMC2705832

Ikediobi O.N., Davies H.R., Bignell G.R., Edkins S., Stevens C., O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L., Buck G., Butler A.P., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C., Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A., Miroo T., Parker A., Perry J., Raine K.M., Richardson D., Shepherd R., Small A., Smith R., Solomon H., Stephens P.J., Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.

Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.

Mol. Cancer Ther. 5:2606-2612(2006)

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113

Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Signatures of mutation and selection in the cancer genome.

Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662

Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Cancer Res. 70:2158-2164(2010)

PubMed=22068913; DOI=10.1073/pnas.1111840108; PMCID=PMC3219108

Gillet J.-P., Calcagno A.M., Varma S., Marino M., Green L.J., Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V., Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R., Ambudkar S.V., Gottesman M.M.

Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.

Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011)

PubMed=22032829; DOI=10.1016/j.mrfmmm.2011.10.005

Luan Y., Kogi M., Rajaguru P., Ren J., Yamaguchi T., Suzuki K., Suzuki T.

Microarray analysis of responsible genes in increased growth rate in the subline of HL60 (HL60RG) cells.

Mutat. Res. 731:20-26(2012)

PubMed=22347499; DOI=10.1371/journal.pone.0031628; PMCID=PMC3276511

Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.

Mass homozygotes accumulation in the NCI-60 cancer cell lines as compared to HapMap trios, and relation to fragile site location.

PLoS ONE 7:E31628-E31628(2012)

PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027

Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Nature 483:603-607(2012)

PubMed=22944676; DOI=10.1515/hsz-2012-0195

Reinke S.O., Bayer M., Berger M., Hinderlich S., Blanchard V.

The analysis of N-glycans of cell membrane proteins from human hematopoietic cell lines reveals distinctions in their pattern.

Biol. Chem. 393:731-747(2012)

PubMed=23955599; DOI=10.1038/ng.2731

Kon A., Shih L.-Y., Minamino M., Sanada M., Shiraishi Y., Nagata Y., Yoshida K.-i., Okuno Y., Bando M., Nakato R., Ishikawa S., Sato-Otsubo A., Nagae G., Nishimoto A., Haferlach C., Nowak D., Sato Y., Alpermann T., Nagasaki M., Shimamura T., Tanaka H., Chiba K., Yamamoto R., Yamaguchi T., Otsu M., Obara N., Sakata-Yanagimoto M., Nakamaki T., Ishiyama K., Nolte F., Hofmann W.-K., Miyawaki S., Chiba S., Mori H., Nakauchi H., Koeffler H.P., Aburatani H., Haferlach T., Shirahige K., Miyano S., Ogawa S.

Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms.

Nat. Genet. 45:1232-1237(2013)

PubMed=24368162; DOI=10.1016/j.exphem.2013.12.004

Sripayap P., Nagai T., Uesawa M., Kobayashi H., Tsukahara T., Ohmine K., Muroi K., Ozawa K.

Mechanisms of resistance to azacitidine in human leukemia cell lines.

Exp. Hematol. 42:294-306.e2(2014)

PubMed=24670534; DOI=10.1371/journal.pone.0092047; PMCID=PMC3966786

Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.

High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.

PLoS ONE 9:E92047-E92047(2014)

PubMed=25984343; DOI=10.1038/sdata.2014.35; PMCID=PMC4432652

Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.

Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.

Sci. Data 1:140035-140035(2014)

PubMed=25485619; DOI=10.1038/nbt.3080

Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.

A comprehensive transcriptional portrait of human cancer cell lines.

Nat. Biotechnol. 33:306-312(2015)

PubMed=25877200; DOI=10.1038/nature14397

Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.

A resource for cell line authentication, annotation and quality control.

Nature 520:307-311(2015)

PubMed=25894527; DOI=10.1371/journal.pone.0121314; PMCID=PMC4404347

Bausch-Fluck D., Hofmann A., Bock T., Frei A.P., Cerciello F., Jacobs A., Moest H., Omasits U., Gundry R.L., Yoon C., Schiess R., Schmidt A., Mirkowska P., Hartlova A.S., Van Eyk J.E., Bourquin J.-P., Aebersold R., Boheler K.R., Zandstra P.W., Wollscheid B.

A mass spectrometric-derived cell surface protein atlas.

PLoS ONE 10:E0121314-E0121314(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878

Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Genome Med. 7:118.1-118.7(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469

Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Miroo T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

A landscape of pharmacogenomic interactions in cancer.

Cell 166:740-754(2016)

PubMed=28109323; DOI=10.1186/s13045-017-0396-0; PMCID=PMC5251306

Masetti R., Bertuccio S.N., Astolfi A., Chiarini F., Lonetti A., Indio V., De Luca M., Bandini J., Serravalle S., Franzoni M., Pigazzi M., Martelli A.M., Basso G., Locatelli F., Pession A.

Hh/Gli antagonist in acute myeloid leukemia with CBFA2T3-GLIS2 fusion gene.

J. Hematol. Oncol. 10:26.1-26.5(2017)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076

Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.

Characterization of human cancer cell lines by reverse-phase protein arrays.

Cancer Cell 31:225-239(2017)

PubMed=29491412; DOI=10.1038/s41388-018-0150-2; PMCID=PMC5955861

Gerlach D., Tontsch-Grunt U., Baum A., Popow J., Scharn D., Hofmann M.H., Engelhardt H., Kaya O., Beck J., Schweifer N., Gerstberger T., Zuber J., Savarese F., Kraut N.

The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML.

Oncogene 37:2687-2701(2018)

PubMed=30285677; DOI=10.1186/s12885-018-4840-5; PMCID=PMC6167786

Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X., Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.H., Koeffler H.P.

Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.

BMC Cancer 18:940.1-940.13(2018)

PubMed=30629668; DOI=10.1371/journal.pone.0210404; PMCID=PMC6328144

Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.

Screening human cell lines for viral infections applying RNA-Seq data analysis.

PLoS ONE 14:E0210404-E0210404(2019)

PubMed=30670178; DOI=10.1016/j.jcf.2018.06.007

Jennings S., Ng H.P., Wang G.-S.

Establishment of a DeltaF508-CF promyelocytic cell line for cystic fibrosis research and drug screening.

J. Cyst. Fibros. 18:44-53(2019)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103

Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Nature 569:503-508(2019)"